Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  PCAS    PCA   FR0000053514

PCAS (PCA)

Delayed Quote. Delayed  - 12/05 02:53:49 pm
11.46 EUR   +2.50%
11/22 PCAS : Acquisition of a leading R&D Center
11/22 PCAS : Acquisition of a leading r&d center
11/04 PCAS : at China INTER LUBRIC 2016
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

PCAS : Extension of the manufacturing between VLG Chem and Sanofi

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/29/2011 | 11:11am CET
Extension of the manufacturing contract between VLG Chem and  Sanofi until 2015 The PCAS Group and the Sanofi Group have signed an agreement on the extension of the manufacturing contract related to VLG Chem, a 100% PCAS subsidiary, until 2015. About PCAS PCAS is a fine and specialty chemicals group that shares an ambition for excellence with its customers, which primarily include market-leading international groups. PCAS designs and delivers the best industrial solutions for its customers' specific expectations. These various expectations all share a common demand for safety, quality, competitiveness, innovation and sustainability.
Longjumeau, december 27th, 2011
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PCAS
11/22 PCAS : Acquisition of a leading R&D Center
11/22 PCAS : Acquisition of a leading r&d center
11/04 PCAS : at China INTER LUBRIC 2016
11/03 PCAS : net sales as of 30 September, 2016
09/14 PCAS : ex-dividend day for interim dividend
09/07 PCAS : 1st half 2016 earnings report continued organic growth
09/02PCAS : half-yearly earnings release
07/19 PCAS : Net sales for the 1st half of 2016
07/19 PCAS : SUSTAINED GROWTH IN NET SALES FOR THE 1st HALF OF 2016
07/13 PCAS : signs a global distribution agreement with MilliporeSigma
More news
Sector news : Pharmaceuticals - NEC
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
12/02DJJOHNSON & JOHNSON : Jury Orders Johnson & Johnson to Pay More Than $1 Billion in..
12/01DJValeant Deal Talks Collapse Over Price -- WSJ
12/01DJCSL : Eyes Biggest Undertaking Yet in Heart Therapy Trial
More sector news : Pharmaceuticals - NEC
Advertisement
Financials (€)
Sales 2016 194 M
EBIT 2016 17,3 M
Net income 2016 9,85 M
Debt 2016 35,6 M
Yield 2016 1,48%
P/E ratio 2016 15,53
P/E ratio 2017 13,39
EV / Sales 2016 1,05x
EV / Sales 2017 1,00x
Capitalization 169 M
More Financials
Chart PCAS
Duration : Period :
PCAS Technical Analysis Chart | PCA | FR0000053514 | 4-Traders
Full-screen chart
Technical analysis trends PCAS
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 12,6 €
Spread / Average Target 12%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Vincent Touraille CEO & Financial Communications Contact
Christian Moretti Chairman
Pierre Schreiner Deputy Chief Executive Officer-Operations
Eric Moissenot Deputy CEO-Finance & Administration
Gérard Guillamot Director-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PCAS40.28%180
JOHNSON & JOHNSON9.00%304 591
PFIZER INC.-2.01%191 942
ROCHE HOLDING LTD.-20.19%188 878
NOVARTIS AG-19.07%178 737
MERCK & CO., INC.15.73%168 544
More Results